Like the United Kingdom at the time, Spain allows the cultivation of medical cannabis on its soil, but does not permit the medical use of cannabis to Spaniards. Cannabis produced in Spain is in fact only for export and is still regulated by a law issued under Franco in 1967.
The Spanish Agency for Medicines and Health Products (AEMPS) granted this month a new authorisation for the production of cannabis for medical purposes to Med Alchemy, belonging to Emmac, a European group based in the United Kingdom, which has acquired Hello Joya in France. The authorisation for cultivation was given after an inspection of the company and the issue of a certificate of compliance with the manufacturing standards necessary for the production of cannabis extracts for medical purposes.
Medalchemy will begin production for the “immediate” distribution of a series of medicinal cannabis products in various countries in Europe and other continents where national legislation permits, an offer that will include “white label” products, according to the press release from Javier Soto, Managing Director of Emmac in Spain.
This licence to produce medical cannabis is the first to be granted during the mandate of the coalition government between PSOE and Podemos. Despite the position of Podemos for a legalization of cannabis, the Spanish government has so far not made any progress on the issues of medical and recreational cannabis in Spain. However, Spanish patients can still cultivate at home or turn to the Cannabis Clubs if they are not able to grow their own cannabis.
In addition to Med Alchemy , three other companies have been granted licences:
Cafina, acquired in April 2019 by Canopy Growth
Linneo Health, heir to Alcaliber, the world leader in morphine-based medicines, sold in 2018 by Torreal and Sanofi to a British investment fund
Oils4cure for a clinical trial